New drug gives hope to Prager and thousands of other Americans, but access still a ways off
The makers of the drug, NVG-291, say offering it through President Trump’s “Right to Try” initiative is neither feasible nor responsible at this time.
A study just getting underway may prove to offer the first cure for spinal cord injury, but getting it to patients still appears a ways off.
Today, about 309,000 Americans are paralyzed. They’ve been told the damage is irreversible because nerves in the spine don’t regrow after scarring from injury. Scientists have for decades struggled with the mystery of “why."
But now there’s additional hope in a drug under development called NVG-291.
Dennis Prager, a national radio talk-show host and podcaster, and co-founder of PragerU, is among those desperate for answers.
“On November 12th, 2024, at about 10 after eight in the morning, my life changed,” Prager told Full Measure in an exclusive interview in South Florida.
A catastrophic fall outside the shower at home left him a quadriplegic. He now battles life-threatening complications such as blood clots and pneumonia.
Then one day, Prager’s wife, Sue, saw reports about a new medicine in the test phase.
“I was particularly blown away by how it works,” she told Full Measure. “My understanding is it essentially reverses the body's message to the injured area that tells the nerves not to regrow and reconnect.”
The medicine is NVG-291, the only drug purportedly ever shown in a clinical trial to promote actual spinal cord nerve repair in people.
Brad Lang was a graduate student in 2009 at the lab of a pioneer in the study of paralysis, the late Dr. Jerry Silver at Case Western Reserve University.
“I like answering big questions and using my life as a scientist to ask the biggest questions,” he says. “And I found one of the biggest questions to be: Why is paralysis permanent? Why is your spinal cord incapable of regenerating? If you can understand why, you can start making therapeutics for that.”
After years of trial and error, Lang and a colleague hit upon an answer. They designed a special short chain of amino acids – a peptide. It caused nerve cells that had been blocked by scar tissue to suddenly grow through it.
In paralyzed animals, the results were dramatic," Lang says. "Rats that dragged their hind legs got NVG-291 and could walk again.
“They regained their autonomic nervous system, which is critically important. That would be your bowel function, your bladder function, and everything else. And then we published this in Nature in 2015. We launched a company, NervGen, in 2016 and we're off to the races with clinical trials."
In 2024, tests were launched to learn whether it works in people. Each patient got daily injections for 12 weeks.
Larry Williams: paralyzed in a mountain-bike crash. After NVG-291, Williams says he can swim, walk faster, stand on his own and that he goes to the gym almost every day.
Niko Paskos: paralyzed in a car accident. After NVG-291, he says he's gained use of his hands and arms, plays wheelchair rugby and skis.
Clay Scherb: paralyzed in diving accident. He says after NVG-291 treatments he’s regained some hand, arm, and lower body function, and can now stand and bear weight, and take steps in a harness.
But all of the hope is tempered by a frustrating reality. NVG-291 won’t be available anytime soon to Prager or the many thousands who are desperate to try something that appears to work.
NervGen told Full Measure that offering NVG-291 through President Trump’s “Right to Try” initiative is neither feasible nor responsible at this time.
“That pathway could receive requests from hundreds or thousands of people, but we do not have the capacity or sufficient drug supply to treat or provide drugs to individuals outside the study," NervGen said. "At this stage, our drug supply, funding, personnel, and operational capacity must be dedicated to the Phase 3 trial.”
The federal government says the goal of this clinical trial is to learn about the safety of NVG-291 and whether the drug can improve function in adults with chronic cervical motor-incomplete spinal cord injury. The main questions the trial aims to answer include: Does NVG-291 improve hand function and daily activities.
Many suffering from paralysis are watching the calendar and regulatory process, hoping the first true repair medicine for the spinal cord comes to them soon.
“There is no other thing out there,” Prager says. “This is it. I mean, it's like telling a thirsty man in the desert, ‘Yeah, there's water there, but, it’s not available to you.’”
For more on this story, watch "Full Measure with Sharyl Attkisson” Sunday. Attkisson's most recent bestseller is "Follow the $cience: How Big Pharma Misleads, Obscures, and Prevails."